Published in J Am Soc Nephrol on January 17, 2007
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol (2008) 1.39
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol (2009) 1.30
Immune dysfunction in uremia—an update. Toxins (Basel) (2012) 1.03
Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol (2009) 0.98
Kinetics of plasmatic cytokines and cystatin C during and after hemodialysis in septic shock-related acute renal failure. Crit Care (2010) 0.97
European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials (2008) 0.94
Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. J Med Case Rep (2008) 0.89
Multiple myeloma and kidney disease. ScientificWorldJournal (2013) 0.80
Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol (2012) 0.80
Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clin Pathol (2012) 0.80
Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Ther Adv Hematol (2013) 0.80
Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clin J Am Soc Nephrol (2016) 0.80
Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur J Med Res (2009) 0.78
Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs (2010) 0.78
Current Trends of Renal Impairment in Multiple Myeloma. Kidney Dis (Basel) (2016) 0.77
Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol (2013) 0.77
Dialysis membrane: from convection to adsorption. NDT Plus (2010) 0.75
Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains in multiple myeloma-induced kidney injury. Indian J Nephrol (2015) 0.75
High cut-off haemodialysis induces remission of recurrent idiopathic focal segmental glomerulosclerosis after renal transplantation but is no alternative to plasmapheresis. NDT Plus (2011) 0.75
The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China. Kidney Dis (Basel) (2016) 0.75
Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS One (2016) 0.75
Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney). Bone Marrow Res (2011) 0.75
Treating myeloma cast nephropathy without treating myeloma. J Clin Invest (2012) 0.75
Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy. PLoS One (2016) 0.75
Treatment of amitriptyline intoxications by extended high cut-off dialysis. Clin Kidney J (2015) 0.75
Multiple myeloma presenting as acute renal failure. Proc (Bayl Univ Med Cent) (2011) 0.75
Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery. Mediterr J Hematol Infect Dis (2013) 0.75
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Serum test for assessment of patients with Bence Jones myeloma. Lancet (2003) 3.04
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood (2012) 2.39
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99
Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ Med (2004) 1.97
The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int (2008) 1.94
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood (2012) 1.75
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant (2012) 1.62
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci (2004) 1.51
A future forum for UK occupational health? Occup Med (Lond) (2012) 1.49
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res (2005) 1.49
Influence of plasma immunoglobulin level on antibody synthesis. Blood (2002) 1.44
Training in occupational medicine: are we as good as we think we are? Occup Med (Lond) (2004) 1.41
Macrophages and progressive tubulointerstitial disease. Kidney Int (2005) 1.40
Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care (2005) 1.39
Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol (2008) 1.39
Appraisal of immunoglobulin free light chain as a marker of response. Blood (2008) 1.38
Integrated media presentation in multidisciplinary head and neck oncology meetings. Eur Arch Otorhinolaryngol (2008) 1.38
Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int (2008) 1.36
Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol (2004) 1.33
Radiation-induced cataracts: the Health Protection Agency's response to the ICRP statement on tissue reactions and recommendation on the dose limit for the eye lens. J Radiol Prot (2012) 1.30
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol (2009) 1.30
The biology of immunoglobulin free light chains and kidney injury. Kidney Int (2011) 1.27
EEG source localization in focal epilepsy: where are we now? Epilepsia (2007) 1.22
Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21
IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem (2003) 1.21
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica (2009) 1.17
Magnetic resonance imaging study in older fragile X premutation male carriers. Ann Neurol (2005) 1.16
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol (2006) 1.13
Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ (2003) 1.12
Tunable pores for measuring concentrations of synthetic and biological nanoparticle dispersions. Biosens Bioelectron (2011) 1.11
Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis (2012) 1.11
Munchausen's syndrome. Lancet (2002) 1.09
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc (2012) 1.09
A new Kv1.2 channelopathy underlying cerebellar ataxia. J Biol Chem (2010) 1.08
Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA (2010) 1.07
Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem (2010) 1.07
Phenotypic and genotypic analysis of Helicoverpa armigera nucleopolyhedrovirus serially passaged in cell culture. J Gen Virol (2002) 1.06
Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.05
CD248+ stromal cells are associated with progressive chronic kidney disease. Kidney Int (2011) 1.04
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol (2011) 1.04
Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs (2008) 1.04
An image-based skeletal tissue model for the ICRP reference newborn. Phys Med Biol (2009) 1.03
Superfluous role of mammalian septins 3 and 5 in neuronal development and synaptic transmission. Mol Cell Biol (2008) 1.00
Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β₁ in patients with chronic kidney disease. Nephron Clin Pract (2011) 1.00
Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia (2004) 0.99
Influenza immunisation: attitudes and beliefs of UK healthcare workers. Occup Environ Med (2006) 0.99
Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation (2005) 0.99
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis (2009) 0.98
Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol (2009) 0.98
Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol (2012) 0.98
Determining the safety of enzymes used in animal feed. Regul Toxicol Pharmacol (2009) 0.97
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol (2012) 0.97
Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis (2007) 0.96
Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol (2005) 0.94
The mechanism distinguishability problem in biochemical kinetics: the single-enzyme, single-substrate reaction as a case study. C R Biol (2005) 0.94
European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials (2008) 0.94
p53 mutations in deep tissues are more strongly associated with recurrence than mutation-positive mucosal margins. Clin Cancer Res (2007) 0.94
Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs (2013) 0.94
Prevalence of health anxiety problems in medical clinics. J Psychosom Res (2011) 0.93
Global attentional-executive sequelae following surgical lesions to globus pallidus interna. Brain (2002) 0.93
Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant (2002) 0.92
Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol (2012) 0.91
Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation. Transplantation (2009) 0.90
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol (2009) 0.90
Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. J Med Case Rep (2008) 0.89
Controlled delivery for neuro-bionic devices. Adv Drug Deliv Rev (2012) 0.89
Rhabdomyolysis and acute kidney injury. N Engl J Med (2009) 0.89
The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma (2006) 0.89
Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int (2009) 0.88
Assessing and comparing rival definitions of delayed renal allograft function for predicting subsequent graft failure. Transplantation (2010) 0.88
The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol (2010) 0.88
Frequency of altered monoclonal protein production at relapse of multiple myeloma. Br J Haematol (2009) 0.88
Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation (2009) 0.88